The Problem of Rarity: Estimation of Prevalence in Rare Disease.

[1]  Caroline Geck,et al.  The World Factbook , 2017 .

[2]  M. Hammer,et al.  Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome , 2017, Epilepsia.

[3]  I. Scheffer,et al.  Mortality in Dravet syndrome , 2016, Epilepsy Research.

[4]  Josemir W Sander,et al.  Mortality in Dravet syndrome: A review , 2016, Epilepsy & Behavior.

[5]  G. Carvill,et al.  Pitfalls in genetic testing: the story of missed SCN1A mutations , 2016, Molecular genetics & genomic medicine.

[6]  A. Berg,et al.  Incidence of Dravet Syndrome in a US Population , 2015, Pediatric neurology briefs.

[7]  T. Hallböök,et al.  Dravet syndrome in Sweden: a population‐based study , 2015, Developmental medicine and child neurology.

[8]  K. Nakken,et al.  Prevalence and etiology of epilepsy in a Norwegian county—A population based study , 2015, Epilepsia.

[9]  Allan Bayat,et al.  The incidence of SCN1A‐related Dravet syndrome in Denmark is 1:22,000: A population‐based study from 2004 to 2009 , 2015, Epilepsia.

[10]  E. Alpsoy,et al.  Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid , 2015, Archives of Dermatological Research.

[11]  J. Kleijnen,et al.  A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases , 2014, Orphanet Journal of Rare Diseases.

[12]  Oriane Trouillard,et al.  De novo mutations in HCN1 cause early infantile epileptic encephalopathy , 2014, Nature Genetics.

[13]  Holger Lerche,et al.  De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. , 2013, American journal of human genetics.

[14]  K. Boycott,et al.  Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.

[15]  I. Scheffer,et al.  SCN1A testing for epilepsy: Application in clinical practice , 2013, Epilepsia.

[16]  S. Shorvon Oxford Textbook of Epilepsy and Epileptic Seizures , 2013 .

[17]  I. Scheffer Diagnosis and long-term course of Dravet syndrome. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  S. Zuberi,et al.  Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. , 2012, Brain : a journal of neurology.

[19]  R. Hubbard,et al.  Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. , 2011, QJM : monthly journal of the Association of Physicians.

[20]  Josemir W Sander,et al.  Standards for epidemiologic studies and surveillance of epilepsy , 2011, Epilepsia.

[21]  I. Scheffer,et al.  Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology , 2011, Brain : a journal of neurology.

[22]  C. Dravet The core Dravet syndrome phenotype , 2011, Epilepsia.

[23]  D. Lindhout,et al.  Adults with a history of possible Dravet syndrome: An illustration of the importance of analysis of the SCN1A gene , 2011, Epilepsia.

[24]  H. Oguni,et al.  Mortality in Dravet syndrome: Search for risk factors in Japanese patients , 2011, Epilepsia.

[25]  P. Camfield,et al.  Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief , 2011, Epilepsia.

[26]  C. Dravet Dravet syndrome history , 2011, Developmental medicine and child neurology.

[27]  J. Huizer,et al.  Recommendations for the development of national plans for rare diseases , 2010, Orphanet Journal of Rare Diseases.

[28]  M. Ruberg,et al.  Sporadic Infantile Epileptic Encephalopathy Caused by Mutations in PCDH19 Resembles Dravet Syndrome but Mainly Affects Females , 2009, PLoS genetics.

[29]  O. Dulac,et al.  Topiramate in the Treatment of Highly Refractory Patients with Dravet Syndrome , 2006, Neuropediatrics.

[30]  C. Chiron Stiripentol , 2005, Neurotherapeutics.

[31]  P. Cras,et al.  "Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy. , 2004, Acta neurologica Belgica.

[32]  Berten Ceulemans,et al.  De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy , 2003, Human mutation.

[33]  Steven Petrou,et al.  Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. , 2002, American journal of human genetics.

[34]  L. Lagae,et al.  De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. , 2001, American journal of human genetics.

[35]  O. Dulac,et al.  Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial , 2000, The Lancet.

[36]  Lawrence Joseph,et al.  Estimating the prevalence of a rare disease: adjusted maximum likelihood , 1998 .

[37]  H. Oguni,et al.  Treatment of Severe Myoclonic Epilepsy in Infants with Bromide and Its Borderline Variant , 1994, Epilepsia.

[38]  I. Jambaqué,et al.  Early diagnosis of severe myoclonic epilepsy in infancy , 1992, Brain and Development.

[39]  D. Hurst Epidemiology of Severe Myoclonic Epilepsy of Infancy , 1990, Epilepsia.

[40]  M. Bureau,et al.  Epilepsie myoclonique grave de la premiere annee , 1982 .

[41]  J. Borén,et al.  [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. , 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.